LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Accueil・Liste d'Actions・Ovid therapeutics Inc

Ovid therapeutics Inc

Fermé

SecteurSoins de santé

2.63 -5.73

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.61

Max

2.65

Chiffres clés
By Trading Economics
Revenu	22M 9.7M
Ventes	586K 718K
Marge bénéficiaire	1,345.822
Employés	23
EBITDA	-152K -12M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+102.66% upside

Dividendes
By Dow Jones
Prochains Résultats	19 mai 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	344M 483M
Ouverture précédente	8.36
Clôture précédente	2.63

Sentiment de l'Actualité

By Acuity

50%

137 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

0.275 / 0.33 Support & Résistance

Ovid therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 mai 2026, 22:47 UTC

Actions en Tendance

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mai 2026, 22:16 UTC

Acquisitions, Fusions, Rachats

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mai 2026, 22:00 UTC

Principaux Mouvements du Marché

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mai 2026, 18:09 UTC

Principaux Mouvements du Marché

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 mai 2026, 16:02 UTC

Résultats

Principaux Mouvements du Marché

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 mai 2026, 14:55 UTC

Principaux Mouvements du Marché

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

16 mai 2026, 16:27 UTC

Acquisitions, Fusions, Rachats

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mai 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 22:17 UTC

Acquisitions, Fusions, Rachats

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:59 UTC

Acquisitions, Fusions, Rachats

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mai 2026, 21:50 UTC

Acquisitions, Fusions, Rachats

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 20:19 UTC

Actions en Tendance

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mai 2026, 19:41 UTC

Acquisitions, Fusions, Rachats

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mai 2026, 18:35 UTC

Résultats

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 mai 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 mai 2026, 16:50 UTC

Acquisitions, Fusions, Rachats

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 mai 2026, 16:24 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15 mai 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 mai 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 mai 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15 mai 2026, 15:20 UTC

Résultats

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

Comparaison

Variation de prix

Ovid therapeutics Inc prévision

Objectif de Prix

By TipRanks

102.66% hausse

Prévisions sur 12 Mois

Moyen 5.33 USD 102.66%

Haut 7 USD

Bas 4 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

0.275 / 0.33Support & Résistance

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

137 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.